NRG ONCOLOGY (RTOG 1306): A Randomized Phase II Study of Individualized Combined Modality Therapy For Stage III Non-Small Cell Lung Cancer (NSCLC).

Print this page

NRG ONCOLOGY (RTOG 1306): A Randomized Phase II Study of Individualized Combined Modality Therapy For Stage III Non-Small Cell Lung Cancer (NSCLC).

OBJECTIVES
Primary Objective:
To assess whether patients with unresectable local-regionally advanced NSCLC treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone.
Secondary Objectives:
To evaluate response rate;
To assess toxicity;
To assess overall survival;
To correlate clinical outcomes with tumor molecular aberrations identified from deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available.

Protocol Number: 031404
Phase: Phase II
Applicable Disease Sites: Lung
Drugs Involved: ETOPOSIDE
Crizotinib
CISPLATIN
CARBOPLATIN
ERLOTINIB
PACLITAXEL
Principal Investigator: Salma Jabbour
Research Nurse: Melissa Frankel
Scope: National
Therapies Involved: Radiotherapy
Chemotherapy multiple agents systemic
Participating Institutions: Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health